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Objective To analyze the incidence and characteristics of documented infections in
patients with hematologic malignancies undergoing unrelated donor bone marrow
transplantation (UD-BMT).
Methods We studied the occurrence of infections in 22 patients with hematologic
malignancies or severe aplastic anemia who underwent UD-BMT from April 1990 to
December 2000. The median age was 26 years (range 13–46). Acyclovir–ganciclovir, co-
trimoxazole, fluconazole–nystatin and ciprofloxacin were administered for anti-infec-
tious prophylaxis.
Results We registered 61 infectious episodes. During the early post-transplant period,
there were eight clinically documented infections (CDIs), four cases of fever of unknown
origin (FUO), seven cases of bacteremia, two cases of cytomegalovirus (CMV) antige-
nemia, and one case of CMV disease. In the intermediate period (days 30–100 after BMT),
there were nine cases of CMV antigenemia, three bacterial infections, two fungal
infections, one case of disseminated toxoplasmosis, and one case of FUO. In the late
period (day 100 and later), we documented 13 viral infections, eight bacterial infections,
one CDI, and one case of invasive aspergillosis. Infections contributed to death in 10 of 17
patients. Citrobacter bacteremia and sepsis of unknown origin were the main causes of
infectious mortality in the early period. Infection was the main cause of death in six of
seven patients in the late period.
Conclusion A high incidence of life-threatening infections and infection-related mor-
tality was observed. A high rate of CMV infection in the early period, and death caused by
multiresistant Gram-negative microorganisms in the late period, were the main findings
in this series.
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I N T R O D U C T I O N
Allogeneic bone marrow transplantation (BMT) is
the treatment of choice in a great variety of malig-
nant and non-malignant hematologic diseases
[1,2]. As only approximately 30% of patients have
a matched sibling donor available, volunteer unre-
lated donor (UD) bone marrow [3], mobilized
peripheral blood [4] and, more recently, umbilical
cord blood [5] are becoming increasingly used as
alternative sources of stem cells.
Infection is recognized as a major cause of mor-
bidity and mortality in patients undergoing allo-
geneic BMT [6], but there is increasing evidence
that infections are more frequent and severe in
cases of UD-BMT as compared with BMT from
HLA-identical siblings [5–10].
We report here an analysis of documented infec-
tions and their related mortality, in the early,
intermediate and late post-transplant periods in
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a series of 22 patients who underwent UD-BMT in
our unit.
P A T I E N T S A N D M E T H O D S
Patients
From April 1990 to December 2000, 22 patients
with hematologic malignancies or severe aplastic
anemia underwent UD-BMT. The disease status of
each patient is shown in Table 1. The median age
was 26 years (range 13–46). All patients received
unmanipulated grafts. Donors and recipients were
both seronegative to cytomegalovirus (CMV) in
five cases.
Histocompatibility
Between 1990 and 1994, HLA class I and II ser-
ologic typing was performed using a standard
microlymphocytotoxicity technique [11]. Since
1994, HLA-A, -B, -C, -DRB1, -DQA1 and -DQB1
low- or high-resolution genotyping was per-
formed by polymerase chain reaction with
sequence-specific primers (PCR-SSP) according
to the method described by Olerup and Zetterquist
[12]. HLA-DPB1 high-resolution genotyping was
performed by PCR and reverse hybridization
with sequence oligonucleotide probes (SSO-PCR)
[13].
Nineteen patients received transplants from an
HLA-identical UD, and three from a single-locus
HLA-mismatched donor, according to the serolo-
gic techniques of class I HLA typing and high-
resolution DNA class II typing.
Conditioning
The conditioning regimen consisted of busulfan,
1 mg/kg every 6 h on days8 to5, and cyclopho-
sphamide, 60 mg/kg per day on days4 and3 in
six patients; busulfan, cyclophosphamide and
antithymocyte globulin (ATG), 15 mg/kg per
day on days5 to2 (Lymphoglobuline, Merieux,
Lyon, France) in 13 patients; thiotepa, 5 mg/kg per
day on days 9 and 8, busulfan, 1 mg/kg every
6 h on days7 to5, cyclophosphamide and ATG
in two patients; and cyclophosphamide plus frac-
tionated total body irradiation (TBI, 13.75 Gy) and
ATG in one patient.
Granulocyte colony-stimulating factor (G-CSF),
5 mg/kg per day by the subcutaneous route, was
administered from day þ7 until the absolute
neutrophil count (ANC) was >1 109/L for 3
consecutive days.
Graft-versus-host disease (GVHD) prophylaxis
and treatment
GVHD prophylaxis consisted of cyclosporine A
(CsA) and a standard short course of methotrexate.
Intravenous CsA was given at a daily dose of
3 mg/kgfrom day1, followedby3–5 mg/kgevery
12 h by mouth when oral intake was feasible, and
tapered down by 10% per week after day þ180.
Acute GVHD was identified clinically and graded
according to modified Seattle criteria [14,15].
Chronic GVHD was assessed as being absent,
limited or extensive [16]. The initial treatment
for acute GVHD consisted of high-dose methyl-
prednisolone, 20 mg/kg per day, halving the dose
every 3 days until reaching 1 mg/kg per day. In
refractory cases, ATG, 15 mg/kg on alternate days,
up to 6–10 doses, depending on response, was
administered. Chronic GVHD was treated with
prednisone, 1 mg/kg per day for 6–9 months.
Infection prophylaxis and treatment
All patients were nursed in high-efficiency parti-
culate air (HEPA)-filtered rooms, and remained in
protective isolation from day 0 to engraftment.
Intravenous access was achieved using venous
double-lumen tunneled central catheters. All
transfused products were irradiated and leukocyte
depleted. Anti-infectious prophylaxis was started
immediately after admittance to the BMT unit. All
patients received ciprofloxacin, 500 mg twice daily
as antibacterial prophylaxis. Prophylaxis against
Pneumocystis carinii pneumonia consisted of co-
trimoxazole (320 mg trimethoprim daily) from
day 10 until day 2; this treatment was recom-
menced after engraftment and maintained while
the patients were on immunosuppressive therapy.
All patients received nystatin, fluconazole and
aerosolized amphotericin B as prophylaxis for
fungal infections. Prophylaxis of CMV infection
in CMV-seropositive patients or in those who
received grafts from CMV-seropositive donors
consisted of acyclovir, 400 mg/m2 every 12 h from
day 5 until engraftment, followed by ganciclovir
(5 mg/kg per day three times a week) until day
þ90. Non-specific intravenous immune globulin
was administered to every patient at a dose of
500 mg/kg weekly to day þ100, and then monthly
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Table 1 Patient characteristics according to pattern of infection
Patient
Underlying
disease and
status at BMT
Year
BMT
CMV status
Donor/
Recipient
G-CSF
Usage
Acute
GVHDa
Chronic
GVHD
Day of
infection Pathogen (s)
Site (s) of
infection
Outcome
follow-up
(days)
Cause of
death
(primary)
1 CML/CP1 1990 Pos/NA No No No þ18 CMV Lung Deadþ 34 CMV
pneumonitis
þ23 Streptococcus
spp.
Blood
2 CML/BC 1991 NA Yes IV NE þ5 ND Oropharynx Deadþ 37 GVHD, IPn
3 CML/CP1 1992 Neg/Pos No I Limited þ7 CoNS Catheter Aliveþ 3256
4 CML/AP 1992 Neg/Neg Yes II NE þ5 ND Oropharynx Deadþ 25 CNS toxicity
þ2 ND –
5 CML/AP 1993 Neg/Neg No III NE þ2 ND –
þ22 Streptococcus
viridans
Blood Deadþ 64 Disseminated
toxoplasmosis
þ64 Toxoplasma
gondii
Brain
6 CML/CP1 1994 Neg/Pos No IV NE þ3 ND Oropharynx Deadþ 53 Acute GVHD
7 AA 1996 Pos/Pos Yes II NE þ16 ND Blood
8 CML/CP1 1996 Neg/Pos Yes III NE 2 Streptococcus
haemolyticus
Blood
þ52 CMV Blood Deadþ 90 IPA
þ90 Aspergillus
niger/fumigatus
Lung
9 CML/CP1 1996 Neg/Pos No II Extensive þ63þ 91 CMV Blood Deadþ 140 CMV
pneumonitis
þ140 CMV Lung
10 CML/CP1 1996 Neg/Pos No IV Limited þ26þ 52 ND – Aliveþ 1515 –
þ570 VZV Mucocutaneous
11 CML/CP1 1997 Neg/Pos No I No þ8 ND Oropharynx Aliveþ 1304 –
12 CML/AP 1997 Neg/Pos Yes IV NE þ8 ND Oropharynx Deadþ 23 Pulmonary
hemorrhage
13 AA 1997 Neg/Pos Yes III Extensive 3 ND Upper airway Deadþ 843 Bacterial
þ54þ 179 CMV Blood
þ853 CMV Esophagus
þ1038 Pseudomonas
aeruginosa
Blood
14 AML/CR2 1997 Neg/Pos Yes No Extensive þ8 ND Oropharynx Deadþ 803 Relapse
15 ALL-T/CR2 1998 Neg/Neg Yes II NE þ14 Citrobacter spp. Lung, blood Deadþ 14 Sepsis
16 ALL/CR2 1998 Neg/Pos Yes II No 0 ND – Deadþ 130 Bacterial
pneumonia
þ60 Listeria
monocytogenes
Blood
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Table 1 continued
Patient
Underlying
disease and
status at BMT
Year
BMT
CMV status
Donor/
Recipient
G-CSF
Usage
Acute
GVHDa
Chronic
GVHD
Day of
infection Pathogen (s)
Site (s) of
infection
Outcome
follow-up
(days)
Cause of
death
(primary)
þ84 Acinetobacter spp. Urinary tract
þ112 Escherichia coli Urinary tract,
blood
þ115 CMV Blood
þ128 Acinetobacter spp. Blood
17 PNH 1998 Neg/Neg Yes III Extensive þ4 Citrobacter spp. Blood Deadþ 340 Aspergillosis
þ228 Aspergillus flavus Epidural space
þ300 Pseudomonas spp. Blood
18 CML/CP1 1998 Neg/Neg Yes IV NE þ8 ND Oropharynx Deadþ 52 Acute GVHD
19 MDS/RAEB 1999 Pos/Pos Yes III Limited þ8 Staphylococcus
cohnii
Blood Aliveþ 709 –
þ68 CMV Blood
20 CML/CP1 1999 Pos/Neg Yes II Extensive þ179 VZV Mucocutaneous Deadþ 664 Nocardiosis
þ343 ND Lung
þ537 HSV Mucocutaneous
þ606 Nocardia Lung/brain
21 AML/CR1 1999 Pos/Pos Yes II Extensive þ7þ 30þ
60þ 148þ
217
CMV Blood Aliveþ 621 –
þ94 Penicillium Lung
þ217 CMV Bloodb
þ503 VZV Mucocutaneous
22 AA 1999 Neg/Pos Yes III Extensive þ 32þ 72þ
93þ 137þ
157þ 212
CMV Blood Deadþ 328 Bacterial
bronchopneu-
monia
þ40 Pseudomonas
aeruginosa
Catheter tunnel
þ195 Campylobacter
jejuni
Gastrointestinal
tract
þ304 Pseudomonas
aeruginosa
Blood/lung
Escherichia coli Blood/lung
aMaximum overall grade. bCMV syndrome. CML, chronic myeloid leukemia; AA, aplastic anemia; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
PNH, paroxysmal nocturnal hemoglobinuria; MDS, myelodysplastic syndrome; RAEB, refractory anemia with excess of blasts; CP1, first chronic phase; CP2, second
chronic phase; AP, accelerated phase; BC, blast crisis; CR1, first complete remission; Pos, positive; Neg, negative; NA, not available; NE, not evaluable; ND, no
documentation; CoNS, coagulase-negative staphylococci; CMV, cytomegalovirus; VZV, varicella zoster virus; HSV, herpes simplex virus; Ipn, interstitial pneumonitis;
IPA, invasive pulmonary aspergillosis; CNS, central nervous system.
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over the first year after transplant. Febrile neutro-
penic patients were initially treated with empirical
intravenous b-lactam antibiotic (piperacillin–tazo-
bactam, meropenem or third-generation cephalos-
porin) in combination with amikacin (single daily
dose of 20 mg/kg body weight, to a maximum of
1.5 g/day). All patients received antibiotic therapy
for a minimum of 7 total days or at least 4 days
beyond their last day of fever. Amikacin was
stopped at day 7 in patients responding to therapy,
and b-lactam monotherapy was continued, if clini-
cally indicated. In patients who remained febrile
after 72 h, antibiotic therapy was modified as part
of a multistep strategy by addition of a glycopep-
tide (vancomycin or teicoplanin). If at any time
during the study the patient’s clinical status wor-
sened (e.g. development of septic shock, progres-
sion of initial infection, or detection of new clinical
sites of infection), the b-lactam was discontinued
and changed to another b-lactam. Antifungal ther-
apy with amphotericin B, either deoxycholate
(0.5–1 mg/kg/day) or liposomal (3 mg/kg/day),
was also initiated if the patient remained febrile
or if his clinical status worsened after 4–6 days
of antibiotic therapy. In patients with a micro-
biologically documented infection, therapy was
modified, if needed, according to susceptibility
testing.
All but the two first patients were routinely
tested for the presence of CMV antigenemia. In
cases of positive CMV antigenemia, we initiated
pre-emptive therapy with ganciclovir, 5 mg/kg
every 12 h for 14 days or until 7 days after the
clearance of CMV antigen from blood—whichever
occurred later—followed by 5 mg/kg per day, 5
days a week for 2 weeks. CMV disease was treated
with ganciclovir at a dose of 5 mg/kg per day for 3
weeks, and intravenous globulin, 0.5 g/kg per day
for 10 days [17].
Infection definitions and microbiological
documentation
Fever was defined as an axillary temperature
38 8C on two occasions at least 1 h apart, or
38.5 8C on at least one occasion. Neutropenia
was defined as an ANC <1 109/L. According
to guidelines issued by the Immunocompromised
Host Society Consensus Conference [18] and the
European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) [19], primary feb-
rile episodes were classified as follows: (1)
microbiologically documented infection (MDI)
with or without bacteremia; (2) clinically docu-
mented infection (CDI); (3) fever of unknown
origin (FUO); and (4) non-infectious fever. A
complete medical history and physical examina-
tion, as well as at least two blood cultures (at 20-
min intervals), were performed before starting the
antibiotic treatment. Cultures of any other sus-
pected site of infection were performed as clini-
cally indicated. When possible, bronchoalveolar
lavage (BAL) or fibrobronchoscopic brushing
was performed in patients with suspected pneu-
monia.
Blood culture samples were drawn through the
two lumens of the catheters and from a peripheral
vein, and continued to be drawn through catheters
daily, if fever persisted. Single blood culture
isolates were sufficient to classify an episode as
bacteremic, except for coagulase-negative staphy-
lococci and for Corynebacterium species other than
Corynebacterium jeikeium, which required at least
two positive blood culture specimens. Oral and
nasal swabs were taken before antibiotic treatment
and repeated at least once weekly. From 1992, all
patients were tested for CMV antigenemia, by
determining leukocyte expression of the CMV-
pp65 antigen twice weekly until day þ120, and
once weekly from days þ120 to þ180. CMV infec-
tion was defined as the isolation of CMV in tissue
culture or by antigenemia using different methods
of detection without clinical manifestation. CMV
pneumonia was confirmed by viral detection in
BAL by any method of detection (PCR, pp65 anti-
gen detection, culture, shell vial), and by the pre-
sence of lung infiltrates on chest X-rays, plus
dyspnea. CMV digestive tract infection was con-
firmed by biopsy showing CMV cell inclusions,
positive immunostaining, immunofluorescence or
in situ hybridization for CMV, or by positive CMV
viral cultures plus symptoms of CMV infection of
the gastrointestinal tract. The ‘CMV syndrome’
was defined by fever, pancytopenia and CMV
antigenemia [20]. All stool samples were examined
microscopically for Cryptosporidium and for other
intestinal parasites, including Giardia lamblia.
Stools were cultured for Salmonella, Shigella, Cam-
pylobacter and Escherichia coli 0157. Liquid stool
samples were also tested for Clostridium difficile
toxin and for viruses. Risk factors for infectious
complications, and the etiology of infections after
BMT, are strongly related to the period of time
since transplant [21]. Thus, in accordance with
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previous recommendations [21,22], three different
risk periods for infection were defined and ana-
lyzed separately: (1) early period (from condition-
ing to day 30); (2) intermediate period (days 30–
100), and (3) late period (beyond day 100).
R E S U L T S
At the time of analysis, five of the patients were
still alive 20–107 months following transplanta-
tion. Engraftment was documented in 19 patients.
The median time to an ANC >0.5 109/L was
18 days (range, 12–28 days). Three patients died
without evidence of engraftment on days 14, 23
and 25 because of Citrobacter freundii sepsis (case
15), pulmonary hemorrhage (case 12), and central
nervous system toxicity (case 4), respectively.
Twenty patients developed acute GVHD (18
grade II–IV and 11 grade III/IV) from days þ6
to þ19. In 12 evaluable patients, chronic GVHD
was limited in three cases and extensive in seven.
All patients developed at least one infectious
episode. In total, 61 infectious episodes were docu-
mented. The types and sites of infection, as well as
the main characteristics associated with them, are
shown in Table 1.
Early infections
We documented 22 infectious episodes in 19
patients. Eight patients had CDI, with severe
mucositis being the most frequent symptom of
infection. One patient had an upper respiratory
tract infection. Four patients had FUO, and one of
these patients died as a result of septic shock.
Seven episodes of bacteremia were documented,
five by Gram-positive and two by Gram-negative
microorganisms. No patient died from Gram-posi-
tive bacteremia, but Gram-negative bacteremia
was the cause of death in one patient (Citrobacter
sp.). Invasive fungal infections were not documen-
ted in any patient during this period. Finally, CMV
infection occurred in two patients; one of them
presented with two reactivation episodes on days
þ7 and þ30, and the remaining patient developed
a CMV-associated pneumonitis that resulted in his
death.
Intermediate-period infections
Eighteen patients survived beyond day þ30. Nine
patients had no infectious episodes during this
period, whereas 16 infectious episodes were docu-
mented in the remaining nine patients. Five of
them had two or more infections. There were three
documented infectious episodes due to Gram-
negative microorganisms: urinary tract infection
with Acinetobacter sp., catheter tunnel abscess due
to Pseudomonas aeruginosa, and primary Gram-
positive bacteremia caused by Listeria monocyto-
genes. Nine episodes of CMV reactivation were
documented in six patients, but there were no
cases of CMV disease. One patient died due to
disseminated toxoplasmosis. Finally, two cases of
fungal infections were documented, one of focal
pneumonia due to Penicillium, and one of invasive
pulmonary aspergillosis due to Aspergillus fumiga-
tus and Aspergillus niger.
Late infections
Twelve patients remained alive at a median fol-
low-up of 23 months after transplantation (range,
4–108 months). Eight of them presented with 23
infections. Six cases of Gram-negative bacteremia
were documented. One case was caused by resis-
tant Acinetobacter baumannii. There were two epi-
sodes of bronchopneumonia, one due to P.
aeruginosa and the other to E. coli. One case
involved urinary tract infection and bacteremia
due to E. coli, and the remaining two cases were
caused by multiresistant Pseudomonas. No infec-
tions due to capsulated bacteria were not
observed. An atypical fungal infection (epidural
abscess) due to Aspergillus flavus was documented,
in a patient with bronchiolitis obliterans. A high
CMV reactivation rate (nine cases) persisted in this
period. CMV antigenemia was detected in four
patients, and two of them developed CMV disease
(enteritis and CMV syndrome). One additional
patient died due to CMV-associated pneumonitis
(CMV antigen in BAL, without antigenemia). We
detected four infections caused by non-CMV
viruses—three by varicella zoster virus (VZV),
and one mucocutaneous genital infection due to
herpes simplex—which resulted in favorable out-
comes. One patient died due to pneumonia and
cerebral abscesses caused by Nocardia asteroides.
Mortality
Overall, 17 of 22 patients died (77%), and infection
was considered to be the main cause of death in 11
of them (50%). Two patients died in the early
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 725–733
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period (sepsis of unknown origin and multiresis-
tant Gram-negative bacteremia due to Citrobacter
sp.), three in the intermediate period (dissemi-
nated toxoplasmosis, pulmonary aspergillosis
and CMV pneumonitis), and six in the late period
(CMV pneumonitis, epidural aspergilloma, disse-
minated nocardiosis, bronchopneumonia/sepsis
due to P. aeruginosa and E. coli, and Acinetobacter
bacteremia).
D I S C U S S I O N
In this analysis of a single institution’s experience,
UD-BMT was complicated by a high rate of life-
threatening infection, especially in the late period.
Most UD-BMT recipients, especially when HLA-
mismatched, suffered complications from acute
and chronic GVHD, leading to an increased risk
of infection [23,24].
The most striking finding of our study was the
high incidence of CMV infections. Eight patients
(36%) developed CMV infection, and three of them
had CMV disease. All cases of CMV infection and
of CMV disease occurred in the 16 patients who
were CMV seropositive before the transplant or
who received marrow from a CMV-seropositive
donor. None of five CMV-seronegative recipients
with a CMV-seronegative donor experienced
CMV infection or disease. Major risk factors for
CMV infection and CMV-associated disease
included seropositivity for CMV before transplant
and the development of acute and chronic GVHD,
which is closely related to the genetic disparity
between donors and recipients [3,24]. The precise
mechanism for the effect of acute GVHD on the
development of CMV-associated disease remains
unclear. CMV-specific cytotoxic T-lymphocytes
are considered to play an important role in the
control of CMV infection. An increased incidence
of CMV infection has been observed in UD trans-
plant patients, even in those without acute GVHD
[9,25,26], suggesting that alloantigen stimulation
by unknown or undefined histocompatibility anti-
gens may be another important factor affecting the
incidence of CMV infection. Given the high inci-
dence of CMV infection after BMT from UDs and
the not infrequent development of CMV disease
without previous detection of CMV antigenemia,
we decided to use a prophylactic strategy for CMV
infection instead of pre-emptive therapy of CMV
reactivation. Although previous reports [27] using
prophylactic therapy, as used in our series,
showed little benefit, the small number of patients
prevents us from drawing conclusions about the
benefit of this strategy. However, pre-emptive
therapy seemed to be effective, since there were
only three cases of CMV disease. CMV pneumo-
nitis was the cause of death in two cases during
atypical periods (early and late). Recently, several
centers have reported an increased frequency of
late onset CMV disease after transplant, probably
due to the continued deficiency of specific immune
responses against CMV [28]. When CMV disease
occurs later, it could be related to resistant CMV
strains [29].
Bacteremia, associated with non-fermenting
Gram-negative bacilli resistant to b-lactam anti-
biotics, was the leading cause of infectious mor-
tality [30–32]. The absence of mortality due to
Gram-positive pathogens argues against the inclu-
sion of glycopeptides in the empirical antibiotic
regimen [19,20,33]. Most remarkable in this series
was an increase in late onset Gram-negative life-
threatening infections. These infections were
strongly associated with chronic extensive GVHD
and its immunosuppressive therapy. In contrast,
capsulated pathogen infections were not observed
in this series.
The rate of invasive fungal infection in our series
(13.6%) was comparable to that reported by others
for allo-BMT. However, some authors have
reported higher rates [10]. Fungal infections
occurred in the intermediate and late periods,
suggesting the efficacy of prophylaxis in the early
period. However, the special severity of these
infections should be kept in mind in transplant
patients, especially those receiving long-term cor-
ticosteroid treatment for chronic GVHD [34]. Early
diagnosis by PCR and/or galactomannan antigen-
based tests are promising methods for monitoring
fungal infections [35,36] in a manner similar to
monitoring CMV infections.
It has been well documented from several small
descriptive studies that respiratory virus infec-
tions can be severe following BMT [37–39], but
such infections were not documented in our series.
Finally, we observed three episodes of infections
due to infrequent pathogens in our series. Listeria
monocytogenes bacteremia without meningitis is
rare, but it has been previously reported in reci-
pients of BMT [10,40,41]. Infection by Nocardia
species has been described in BMT recipients,
especially in the late period [42,43], as occurred
in one of our patients with extensive chronic
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GVHD. Disseminated toxoplasmosis has been con-
sidered a rare opportunistic infection, as reported
previously in the literature [44–46]. Serologic fol-
low-up of recipients of BMT was of limited diag-
nostic value, and the definitive proof of infection
was usually obtained by the demonstration of
Toxoplasma gondii in blood or tissues.
In conclusion, we have confirmed a high inci-
dence of severe infections among patients under-
going UD-BMT. Noteworthy are the early
appearance of CMV infections and the high death
rate associated with multiresistant Gram-negative
bacteremia. Improvements in early diagnosis, anti-
infectious prophylaxis and therapeutic strategies
may contribute substantially to a significant
decrease in both infectious morbidity and mortal-
ity, and to improving clinical results.
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